Lingrui Pharmaceutical Shares Slide 9.22% on Net Sell of RMB 106 Million

On August 12, Lingrui Pharmaceutical's shares fell 9.22%, with a turnover rate of 7.74%, turnover of RMB 902 million, and amplitude of 2.40%. According to Shanghai Stock Exchange public information, the stock was listed on the Dragon-Tiger List due to a daily decline deviation of -9.54%. Institutional special seats had a combined net sell of RMB 19.6123 million, Shanghai-Hong Kong Stock Connect net sold RMB 56.8569 million, and business department seats net sold RMB 29.7638 million. The top five buying and selling departments on the list had a combined turnover of RMB 272 million, with buy turnover of RMB 82.6819 million and sell turnover of RMB 189 million, resulting in a net sell of RMB 106 million.

On that day, three institutional special seats appeared on the list, at buy position 1, sell position 3, and sell position 4, with total buy amount of RMB 24.8545 million and sell amount of RMB 44.4668 million, net selling RMB 19.6123 million. Stock Connect was the third largest buying department and the largest selling department, with buy amount of RMB 15.64 million and sell amount of RMB 72.4969 million, net selling RMB 56.8569 million. On the buy side, CITIC Securities Beijing Tiantongyuan Securities Department bought RMB 22.768 million, East Money Securities Lhasa East Ring Road Second Securities Department bought RMB 11.1847 million, and East Money Securities Lhasa Financial City South Ring Road Securities Department bought RMB 8.2348 million. On the sell side, Yuekai Securities Panjin Shiyou Street Securities Department sold RMB 52.9607 million, and UBS Securities Shanghai Garden Stone Bridge Road Securities Department sold RMB 18.9905 million.

Fund flow data shows that the stock had a net main capital outflow of RMB 45.9604 million, with super-large orders net outflow of RMB 30.5183 million and large orders net outflow of RMB 15.4421 million. Over the past five days, main capital had a cumulative net outflow of RMB 14.5752 million. Margin trading data shows that as of August 11, the stock's margin balance was RMB 365 million, with financing balance of RMB 364 million and securities lending balance of RMB 1.0463 million. Over the past five days, financing balance increased by RMB 31.5399 million, up 9.49%, while securities lending balance decreased by RMB 336,600, down 24.34%.

Lingrui Pharmaceutical, founded in 1961, released its interim report on August 12, showing that in the first half of 2026, the company achieved operating revenue of RMB 2.148 billion, up 2.32% year-on-year, and net profit of RMB 495 million, up 4.36% year-on-year.